
Wei-Ming Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/610702/publications.pdf Version: 2024-02-01



WELMING LL

#	Article	IF	CITATIONS
1	COVID-19 in persons with chronic myeloid leukaemia. Leukemia, 2020, 34, 1799-1804.	7.2	74
2	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	31
3	Epstein barr virus encodes miRNAs to assist host immune escape. Journal of Cancer, 2020, 11, 2091-2100.	2.5	18
4	Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials. Blood, 2020, 136, 50-51.	1.4	18
5	A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. Leukemia, 2021, 35, 119-129.	7.2	15
6	miR-125b regulates cell progression in chronic myeloid leukemia via targeting BAK1. American Journal of Translational Research (discontinued), 2016, 8, 447-59.	0.0	14
7	Comparison of outcomes of idarubicin intensified TBI–CY and traditional TBI–CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience. Leukemia Research, 2015, 39, 1192-1200.	0.8	13
8	Development of pancytopenia in a patient with COVIDâ€19. Journal of Medical Virology, 2021, 93, 1219-1220.	5.0	12
9	Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Leukemia Research, 2016, 46, 61-68.	0.8	11
10	Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells. Frontiers in Oncology, 2021, 11, 769730.	2.8	10
11	Monitoring of leukemia stem cells in chronic myeloid leukemia patients. Leukemia and Lymphoma, 2018, 59, 2264-2266.	1.3	9
12	Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i> -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). Blood, 2021, 138, 3598-3598.	1.4	9
13	Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI. Frontiers in Oncology, 2021, 11, 739871.	2.8	7
14	A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget, 2016, 7, 58234-58243.	1.8	7
15	MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia. American Journal of Translational Research (discontinued), 2016, 8, 955-67.	0.0	7
16	HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia. Disease Markers, 2022, 2022, 1-22.	1.3	7
17	Analysis of seizure risk factors after allogeneic hematopoietic stem cell transplantation: A 8 case report and literature review. Journal of Huazhong University of Science and Technology [Medical Sciences], 2013, 33, 656-660.	1.0	6
18	A novel e8a2 BCR-ABL1 intronic fusion through insertion of a chromosome 22 BCR gene fragment into chromosome 9 in an atypical Philadelphia (Ph) chromosome chronic myeloid leukemia patient. Leukemia and Lymphoma, 2016, 57, 2930-2933.	1.3	4

Wei-Ming Li

#	Article	IF	CITATIONS
19	Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e43-e49.	0.4	4
20	Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services. Frontiers in Psychiatry, 2021, 12, 679932.	2.6	4
21	Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China. Haematologica, 2022, 107, 1966-1970.	3.5	4
22	Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China. Current Medical Science, 2018, 38, 1005-1011.	1.8	3
23	Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia. Current Medical Science, 2019, 39, 217-221.	1.8	3
24	EpsteinBarr virusencoded microRNAs involve in tumorigenesis and development. Journal of Central South University (Medical Sciences), 2021, 46, 300-308.	0.1	1
25	Initial study on immune escape mechanism of mouse acute myelomonocytic leukemic cell line WEHI-3. Chinese-German Journal of Clinical Oncology, 2006, 5, 291-293.	0.1	0
26	Gene and protein expression of proteinase-activated receptor-1, 2 in a murine model of acute graft vs host disease. Frontiers of Medicine in China, 2009, 3, 309-315.	0.1	0
27	The Comparison of Dasatinib 70 Mg/Day to 100 Mg/Day in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Multicenter, Prospective, Randomized Controlled Study. Blood, 2021, 138, 3615-3615.	1.4	0